A Phase 4 interventional study of KAM2904 Face Cream and KAM3008 Body Lotion in Atopic Dermatitis, sponsored by Kamedis Ltd.. Status unknown at 1 site in Spain. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2014-01-30.
Sponsored by Kamedis Ltd. · Phase 4, Interventional, and Treatment
The main purpose of this study is to demonstrate the safety and efficacy of KAM2904 Face Cream and KAM3008 Body Lotion in reducing the symptoms of mild to moderate AD. Efficacy will be evaluated by comparing SCORAD and Eczema Area Severity Index (EASI) in a group of subjects treated with KAM2904 Face Cream and KAM3008 Body Lotion (the treatment group), versus a group of subjects treated with a petrolatum-based moisturizer (the control group). Safety will be determined by the number and severity of Adverse Events Device-Related.
1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.
This study's planned enrollment of 56 is below the median of 83 across 1,125 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Kamedis Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male or female between 2 and 12 years of age
Exclusion Criteria:
The subject has another dermatological disease/condition that could interfere with the clinical evaluation, including infected atopic dermatitis lesions
A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
Device: KAM2904 Face Cream · Device: KAM3008 Body Lotion
control group
Other: petrolatum-based moisturizer
• Change in SCORAD (Scoring Atopic Dermatitis)
Time frame: after 42 days of treatment
• Change in EASI (Eczema Area Severity Index)
Time frame: after 42 days of treatment
• Change in the scoring of individual symptoms of atopic dermatitis
Time frame: after 42 days of treatment
• Trend in the change of SCORAD
Time frame: after 42 days of treatment
• Trend in the change of EASI
Time frame: after 42 days of treatment
• Trend in the change of individual symptoms of atopic dermatitis
Time frame: after 42 days of treatment
• Safety of KAM2904 Face Cream and KAM3008 Body Lotion
Safety will be measured by the number and severity of Device-Related Adverse Events.
Time frame: days D14, D28, D42 and unscheduled visits
This study is status unknown, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.